What does Fujian Haixi Pharmaceuticals do?

Fujian Haixi Pharmaceuticals develops, makes and sells prescription medicines in China, mostly lower-cost generic versions of established drugs. Its products treat conditions such as high blood pressure, high cholesterol, digestive problems, depression, allergies and inflammation. It is also developing its own new drugs for cancer, eye disease and lung fibrosis.

Healthcare · Drug Manufacturers - Specialty & Generic · 2637.HK

What Fujian Haixi Pharmaceuticals Does & How It Makes Money (2637.HK)

Updated October 2026 · reflects Fujian Haixi Pharmaceuticals's latest reported financials

Chinese generic drug maker with an early-stage innovative drug pipeline. It earns most of its revenue by selling generic drugs through retail pharmacies, online pharmacies and internet medical platforms, plus some income from pharmaceutical technical services.

Fujian Haixi Pharmaceuticals's story, moat and numbers — in a 3-minute visual book.

Explore Fujian Haixi Pharmaceuticals on TacticScale →

How Fujian Haixi Pharmaceuticals makes money

It earns most of its revenue by selling generic drugs through retail pharmacies, online pharmacies and internet medical platforms, plus some income from pharmaceutical technical services.

What Fujian Haixi Pharmaceuticals does

Fujian Haixi Pharmaceuticals, founded in 2012 and based in Fuzhou, is a Chinese drugmaker whose commercial business is built on generic medicines. Its portfolio covers cardiovascular drugs (Haihuitong, Haibiping, Haikexi), digestive treatments (Anbili), mental health (Anyoufan), kidney-related mineral disorders (Ruiantuo), autoimmune conditions (Saixifu), anti-inflammatories (Anfeiping) and allergy medicine (Jishuning). It sells them through retail pharmacies, online pharmacies and internet medical platforms, and also offers pharmaceutical technical services. Beyond generics, the company is developing its own innovative drugs. Its most advanced candidate, C019199, has completed Phase II trials for advanced osteosarcoma and works by targeting the tumor's immunosuppressive environment. Earlier-stage oral small-molecule drugs include HXP056 for retinopathy-related diseases (Phase I completed), HXP089 for glioblastoma and HXP090 for idiopathic pulmonary fibrosis.

Products & services

Anbili (mosapride citrate)
Haihuitong (amlodipine/atorvastatin)
Ruiantuo (cinacalcet)
Saixifu (hydroxychloroquine)
Haibiping (valsartan/amlodipine)
C019199 (osteosarcoma candidate)

What is Fujian Haixi Pharmaceuticals worth?

Fair value: not published

A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.

We show a fair value only when the method is trustworthy. See Fujian Haixi Pharmaceuticals on TacticScale →

Sector Healthcare Industry Drug Manufacturers - Specialty & Generic HQ China Ticker 2637.HK Official site

Related companies

Zhejiang Jingxin Pharmaceutical (002020.SZ) · Zhejiang Huahai Pharmaceutical (600521.SS) · Zhejiang Hisun Pharmaceutical (600267.SS) · Jiangsu Hengrui Pharmaceuticals (600276.SS) · Shanghai Fosun Pharmaceutical (600196.SS)

Understand Fujian Haixi Pharmaceuticals in 3 minutes →